JP Morgan Chase’s Verrica Pharmaceuticals VRCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $306 | Hold |
47
| – | – | ﹤0.01% | 7466 |
|
|
2026
Q1 | $224 | Hold |
47
| – | – | ﹤0.01% | 7243 |
|
|
2025
Q4 | $391 | Buy |
+47
| New | +$260 | ﹤0.01% | 7100 |
|
|
2025
Q2 | – | Sell |
-2,031
| Closed | -$8.98K | – | 7682 |
|
|
2025
Q1 | $8.98K | Buy |
2,031
+1,079
| +113% | +$6.98K | ﹤0.01% | 6327 |
|
|
2024
Q4 | $6.66K | Buy |
952
+65
| +7% | +$714 | ﹤0.01% | 6459 |
|
|
2024
Q3 | $12.9K | Buy |
887
+22
| +3% | +$991 | ﹤0.01% | 6322 |
|
|
2024
Q2 | $63.1K | Sell |
865
-10
| -1% | -$768 | ﹤0.01% | 5757 |
|
|
2024
Q1 | $51.8K | Sell |
875
-484
| -36% | -$26.7K | ﹤0.01% | 5925 |
|
|
2023
Q4 | $100K | Hold |
1,359
| – | – | ﹤0.01% | 5734 |
|
|
2023
Q3 | $52.8K | Sell |
1,359
-428
| -24% | -$21.8K | ﹤0.01% | 5785 |
|
|
2023
Q2 | $103K | Buy |
1,787
+1,663
| +1,341% | +$101K | ﹤0.01% | 5441 |
|
|
2023
Q1 | $8K | Hold |
124
| – | – | ﹤0.01% | 6174 |
|
|
2022
Q4 | $3K | Sell |
124
-146
| -54% | -$3.9K | ﹤0.01% | 6267 |
|
|
2022
Q3 | $8K | Buy |
270
+162
| +150% | +$5.55K | ﹤0.01% | 6008 |
|
|
2022
Q2 | $2K | Sell |
108
-829
| -88% | -$41.7K | ﹤0.01% | 6309 |
|
|
2022
Q1 | $76K | Sell |
937
-1,522
| -62% | -$125K | ﹤0.01% | 5626 |
|
|
2021
Q4 | $225K | Sell |
2,459
-592
| -19% | -$67K | ﹤0.01% | 5287 |
|
|
2021
Q3 | $382K | Sell |
3,051
-1,283
| -30% | -$144K | ﹤0.01% | 4878 |
|
|
2021
Q2 | $490K | Buy |
4,334
+1,560
| +56% | +$189K | ﹤0.01% | 4709 |
|
|
2021
Q1 | $421K | Buy |
2,774
+2,223
| +403% | +$308K | ﹤0.01% | 4788 |
|
|
2020
Q4 | $63K | Buy |
551
+87
| +19% | +$8K | ﹤0.01% | 5105 |
|
|
2020
Q3 | $37K | Sell |
464
-88
| -16% | -$7.21K | ﹤0.01% | 5024 |
|
|
2020
Q2 | $60K | Buy |
552
+137
| +33% | +$15.8K | ﹤0.01% | 4775 |
|
|
2020
Q1 | $45K | Sell |
415
-10
| -2% | -$1.32K | ﹤0.01% | 4759 |
|
|
2019
Q4 | $67K | Buy |
425
+2
| +0.5% | +$295 | ﹤0.01% | 5031 |
|
|
2019
Q3 | $62K | Buy |
423
+69
| +19% | +$7.69K | ﹤0.01% | 5080 |
|
|
2019
Q2 | $34K | Buy |
354
+93
| +36% | +$8.72K | ﹤0.01% | 5314 |
|
|
2019
Q1 | $28K | Sell |
261
-999
| -79% | -$115K | ﹤0.01% | 5316 |
|
|
2018
Q4 | $103K | Buy |
1,260
+1,126
| +840% | +$137K | ﹤0.01% | 4842 |
|
|
2018
Q3 | $22K | Buy |
+134
| New | +$22.9K | ﹤0.01% | 5406 |
|
Other funds holding VRCA
JP Morgan Chase's VRCA Position: Q2 2026 in Review
JP Morgan Chase held its Verrica Pharmaceuticals (VRCA) position steady in Q2 2026 at 47 shares worth $306. The position accounts for ﹤0.01% of the portfolio, ranked #7466.
JP Morgan Chase first reported a position in VRCA in Q3 2018 and has held it in 30 quarters since. The position peaked at $490K in Q2 2021. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.
- JP Morgan Chase held 47 shares of Verrica Pharmaceuticals worth $306 as of Q2 2026.
- JP Morgan Chase left its Verrica Pharmaceuticals share count unchanged in Q2 2026.
- Verrica Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7466 holding.
- JP Morgan Chase first reported a position in Verrica Pharmaceuticals in Q3 2018 and has held it in 30 quarters since.
- JP Morgan Chase's Verrica Pharmaceuticals position peaked at $490K in Q2 2021.
- 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.